Skip to main content

Advertisement

Log in

Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

  • Case Report
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

The purpose of this study is to report a case of retinal capillary hemangioma treated with ruthenium-106 brachytherapy combined with intravitreal bevacizumab. A 58-year-old woman presented with blurred vision in her left eye for 15 days. Best-corrected visual acuity (BCVA) was counting fingers at 3 m in her left eye. Examination showed a peripheral endophytic retinal capillary hemangioma, with associated macular edema and diffuse hard exudates in a macular star pattern. B-scan ultrasonography revealed a solid, highly reflective retinal tumor measuring 7.1 × 7.5 mm in basal dimension and 3.5 mm in thickness. The hemangioma and macular edema were treated with ruthenium-106 brachytherapy (500 Gy) followed 1 month later with an intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. After 10 months of follow-up, examination demonstrated involution of the hemangioma, resolution of the macular edema, less hard exudates, and improvement of BCVA to 20/25. Ruthenium-106 brachytherapy combined with intravitreal bevacizumab was associated with significant involution of the choroidal hemangioma with resolution of the macular edema and improvement in visual acuity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Webster AR, Maher ER, Bird AC, Gregor ZJ, Moore AT (1999) A clinical and molecular genetic analysis of solitary ocular angioma. Ophthalmology 106:623–629. doi:10.1016/S0161-6420(99)90127-6

    Article  PubMed  CAS  Google Scholar 

  2. Rodriguez-Coleman H, Spaide RF, Yannuzzi LA (2002) Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina 22:228–232. doi:10.1097/00006982-200204000-00019

    Article  PubMed  Google Scholar 

  3. Los M, Aarsman CJ, Terpstra L et al (1997) Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann Oncol 8:1015–1022. doi:10.1023/A:1008213320642

    Article  PubMed  CAS  Google Scholar 

  4. Chan CC, Vortmeyer AO, Chew EY et al (1999) VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol 117:625–630

    PubMed  CAS  Google Scholar 

  5. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278. doi:10.1097/00006982-200603000-00004

    Article  PubMed  Google Scholar 

  6. Kreusel KM, Bornfeld N, Lommatzsch A, Wessing A, Foerster MH (1998) Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology 105(8):1386–1392. doi:10.1016/S0161-6420(98)98017-4

    Article  PubMed  CAS  Google Scholar 

  7. Murthy R, Hanovaz SG, Naik M, Gopi S, Reddy VA (2005) Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal haemangioma in Sturge–Weber syndrome. Indian J Ophthalmol 53:274–275

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Antonio Barone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Russo, V., Stella, A., Barone, A. et al. Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma. Int Ophthalmol 32, 71–75 (2012). https://doi.org/10.1007/s10792-011-9513-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-011-9513-1

Keywords

Navigation